FBRX vs. KOD, ATYR, AQST, ESPR, IVA, RAPP, CYRX, ZVRA, PRME, and BCYC
Should you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Kodiak Sciences (KOD), aTyr Pharma (ATYR), Aquestive Therapeutics (AQST), Esperion Therapeutics (ESPR), Inventiva (IVA), Rapport Therapeutics (RAPP), CryoPort (CYRX), Zevra Therapeutics (ZVRA), Prime Medicine (PRME), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry.
Forte Biosciences vs. Its Competitors
Kodiak Sciences (NASDAQ:KOD) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.
In the previous week, Kodiak Sciences had 1 more articles in the media than Forte Biosciences. MarketBeat recorded 6 mentions for Kodiak Sciences and 5 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.37 beat Kodiak Sciences' score of 0.21 indicating that Forte Biosciences is being referred to more favorably in the news media.
Kodiak Sciences is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.
Kodiak Sciences presently has a consensus target price of $11.75, suggesting a potential upside of 18.45%. Forte Biosciences has a consensus target price of $68.00, suggesting a potential upside of 550.10%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Forte Biosciences is more favorable than Kodiak Sciences.
Kodiak Sciences has a beta of 2.45, suggesting that its stock price is 145% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.69, suggesting that its stock price is 169% more volatile than the S&P 500.
Forte Biosciences' return on equity of -85.38% beat Kodiak Sciences' return on equity.
89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 45.9% of Kodiak Sciences shares are held by insiders. Comparatively, 5.9% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Forte Biosciences beats Kodiak Sciences on 8 of the 13 factors compared between the two stocks.
Get Forte Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Forte Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:FBRX) was last updated on 9/12/2025 by MarketBeat.com Staff
Free FBRX Stock Alerts